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Abstract
Solvents can be used in the manufacture of medicinal products provided their residual levels in the final product
comply with the acceptable limits based on safety data. At worldwide level, these limits are set by the “Guideline
Q3C (R6) on impurities: guideline for residual solvents” issued by the ICH. Diisopropyl ether (DIPE) is a widely
used solvent but the possibility of using it in the pharmaceutical manufacture is uncertain because the ICH Q3C
guideline includes it in the group of solvents for which “no adequate toxicological data on which to base a Permit-
ted Daily Exposure (PDE) was found”. We performed a risk assessment of DIPE based on available toxicological
data, after carefully assessing their reliability using the Klimisch score approach. We found sufficiently reliable
studies investigating subchronic, developmental, neurological toxicity and carcinogenicity in rats and genotoxic-
ity in vitro. Recent studies also investigated a wide array of toxic effects of gasoline/DIPE mixtures as compared
to gasoline alone, thus allowing identifying the effects of DIPE itself. These data allowed a comprehensive toxico-
logical evaluation of DIPE. The main target organs of DIPE toxicity were liver and kidney. DIPE was not terato-
gen and had no genotoxic effects, either in vitro or in vivo. However, it appeared to increase the number of
malignant tumors in rats. Therefore, DIPE could be considered as a non-genotoxic animal carcinogen and a PDE
of 0.98 mg/day was calculated based on the lowest No Observed Effect Level (NOEL) value of 356 mg/m3 (corre-
sponding to 49 mg/kg/day) for maternal toxicity in developmental rat toxicity study. In a worst-case scenario,
using an exceedingly high daily dose of 10 g/day, allowed DIPE concentration in pharmaceutical substances
would be 98 ppm, which is in the range of concentration limits for ICH Q3C guideline class 2 solvents. This result
might be considered for regulatory decisions.
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INTRODUCTION
Diisopropyl ether (DIPE, also known as isopropyl ether;
CAS number 108-20-3) is a widely used solvent included
in the High Production Volume Chemical list issued by the
Organisation for Economic Co-operation and Develop-
ment (OECD) (1). Due to its physicochemical properties,
DIPE is effective for the extraction of polar or mid-polar
compounds. In the pharmaceutical industry, DIPE is used
in the manufacture of Active Pharmaceutical Ingredients
(APIs), mainly as an extractant and for purification by
crystallization of several compounds, particularly steroids
(2,3).
Solvents can be used in the manufacture of medicinal
products provided their residual levels in the finished
product comply with the acceptable limits set by regula-
tory agencies based on safety data. At worldwide level,
the acceptable limits of residual solvents are defined in the
“Guideline Q3C (R6) on impurities: guideline for residual
solvents” issued by the International Conference on Har-
monisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH) (4). The objective
of this guideline is to recommend acceptable amounts for
residual solvents in pharmaceuticals for the safety of the
patient. The ICH Q3C Guideline classifies solvents in one
of the following three classes: solvents to be avoided
(class 1); solvents to be limited (class 2), for which a Per-
mitted Daily Exposure (PDE) should be established; sol-
vents with low toxic potential (class 3).
The ICH Q3C guideline includes DIPE in a further
group of solvents for which “no adequate toxicological
data on which to base a Permitted Daily Exposure (PDE)
was found”. The use of these solvents is theoretically pos-
sible upon justification for their residual levels. In prac-
tice, this situation creates a state of uncertainty regarding
the regulatory status of DIPE and the possibility of using it
in pharmaceutical manufacture.
The first version of ICH Q3C guideline was finalised in
July 1997 but since then new studies on DIPE toxicity
have been produced, which should make it possible to per-
form a risk assessment of DIPE. This assessment may
contribute to regulatory decisions on the classification of
DIPE according to the ICH Q3C guideline, thus helping
resolving the uncertainty about its possible use. Revision
of classification is in agreement with the principles laid
down in the part II of the ICH Q3C guideline for which
PDEs could be calculated/updated as new reliable safety
data become available.
The aim of the present work was to perform a risk
assessment of DIPE based on available toxicological data,
whose reliability is confirmed in agreement with the rec-
ommendations of the ICH Q3C guideline. According to
the guideline, toxicological data used for risk assessment
should derive from studies adopting adequately sound pro-
tocols such as those described for example by OECD or
the United States Environment Protection Agency (EPA)
guidelines. It is therefore essential to evaluate accurately
the reliability of the available toxicological data. We assessed
the compliance of retrieved toxicological data with exist-
ing guidelines and evaluated the data reliability using the
Klimisch score approach, which was originally proposed
by Klimisch and co-workers (5) and is now widely accepted.
This approach has also been adopted by the European
Chemicals Agency (ECHA) for assessing the data provided
to fulfil the obligations of the Registration, Evaluation,
Authorisation and Restriction of Chemicals (REACH)
regulation. Once determined the lowest No Observed
Effect Level (NOEL) value based on available data, we
derived the PDE value in agreement with the ICH Q3C
guideline.
MATERIALS AND METHODS
Data search. We conducted a literature search from
the PubMed database using the Medical Subject Heading
(MeSH) term ‘Diisopropyl ether’ combined with the MeSH
terms ‘Toxicity’, ‘Toxicity tests’, ‘Toxicity test, subacute’,
‘Toxicity test, subchronic’, ‘Toxicity test, chronic’, ‘Muta-
genicity tests’. Toxicokinetic data were searched by using
the MeSH term ‘Diisopropyl ether’ combined with the
MeSH term ‘Toxicokinetics’. Data on the metabolism of
structurally related ethers were searched by using the
MeSH term “Ether/metabolism” (or similar for specific
classes of ethers, such as methyl ethers). We also searched
Google and Google Scholar using the same terms as above.
Once found a relevant paper in PubMed, the search was
extended to related articles. References cited in relevant
articles were also evaluated. Finally, toxicological data
were also searched in the most relevant databases (Tox-
net, ECHA, National Institute for Occupational Safety and
Health).
Assessment of data reliability. The reliability of
retrieved data was assessed according to Klimisch and co-
workers approach (5), which is based on compliance with
generally valid and/or internationally accepted testing
guidelines; agreement with the principles of Good Labora-
tory Practice (GLP); completeness and scientific sound-
ness of the documentation. Klimisch scores are shown in
Table 1. The GLP status of several retrieved published in
vitro and in vivo toxicity studies is unknown. However, it
is important to note that studies not complying with GLP
may nevertheless be considered reliable according to the
Klimisch score approach (i.e., having a score 1 or 2).
In assigning the Klimisch score, we also followed the
recommendations of the ECHA guidance on information
requirements and chemical safety assessment. For each
toxicological study, we verified the compliance to testing
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guidelines issued by EPA or OECD. Only data with a Kli-
misch score 1 or 2 were considered for the risk assessment.
Calculation of PDE and acceptable limits. PDE (mg/
day) for DIPE was calculated in agreement with the fol-
lowing ICH Q3C guideline Appendix 3 formula:
PDE (mg/day) = NOEL (mg/kg/day)
× weight adjustment ÷ (F1 × F2 × F3 × F4 × F5)
(modifying factors)
We used the lowest value among all NOEL values derived
from published data. Because in all selected animal stud-
ies exposure to DIPE occurred through inhalation (with
the exception of the carcinogenicity study), the inhaled
concentration was transformed into a weight/weight dose.
Therefore, the inhaled concentration was first converted
from ppm to mg/m3 (mg/m3 = ppm × molecular weight/
24.45, based on the following conditions: temperature
25oC; pressure 1 atmosphere). In order to calculate the
absorbed dose, this value was multiplied for the respira-
tory volume (0.29 m3/day) in the rat (the species used in
all relevant studies), assuming a complete bioavailability
and the dose was then divided by the reported weight:
Concentration (mg/m3) × 0.29 m3/day ÷ W (kg)
= absorbed dose (mg/kg).
To calculate the NOEL, the absorbed dose value was cor-
rected for discontinuous exposure (6 hr/day for 5 days/
week) and converted into a continuous one:
Absorbed dose (mg/kg) × 6 hr ÷ 24 hr × 5 day/7 day
= NOEL (mg/kg/day).
PDE was obtained by multiplying the NOEL by 50 kg
(weight adjustment) and dividing this value by the appro-
priate modifying factors. According to the ICH Q3C
guideline, the modifying factors are as follows. F1 is a
factor to account for extrapolation between species. Its
value depends on the species used in the study (for rat,
F1 = 5). F2 is a factor of 10 to account for variability
between individuals. F3 is a variable factor to account for
extrapolation from short-term toxicity studies to lifetime
exposure. F4 is an additional factor that may be applied in
cases of severe toxicity, e.g., non-genotoxic carcinogenic-
ity, neurotoxicity or teratogenicity. F5 is a further variable
factor that may be applied if the NOEL was not estab-
lished.
The acceptable residual concentration (ppm) in an API
was calculated as:
Concentration = 1,000 × PDE/
dose, where PDE is expressed as mg/
day and the dose as g/day.
RESULTS
The selected toxicity studies for DIPE risk assessment
are summarised in Table 2.
Six recently published studies thoroughly characterised
the toxicity of gasoline combined with oxygenated fuel
additives, including DIPE (6-11). In these studies, a con-
trol group exposed to gasoline alone was used (in addition
to controls). This protocol allowed identifying the effects
of DIPE and using these mixture studies in risk assess-
ment.
Data on toxicokinetic or metabolism of DIPE were not
available. However, we found data on the metabolism of
substances structurally related to DIPE, i.e., low molecu-
lar weight aliphatic ethers such as diethyl ether (DEE),
methyl tert-butyl ether (MTBE), ethyl tert-butyl ether
(ETBE) and tert-amyl methyl ether (TAME).
Table 1. Klimisch scores
Score Reliability Description
1
Reliable without
restrictions
Studies or data [...] generated according to generally valid and/or internationally accepted testing guide-
lines (preferably performed according to GLP) or in which the test parameters documented are based on
a specific (national) testing guideline [...] or in which all parameters described are closely related/compa-
rable to a guideline method.
2
Reliable with
restrictions
Studies or data [...] (mostly not performed according to GLP), in which the test parameters documented
do not totally comply with the specific testing guideline, but are sufficient to accept the data or in which
investigations are described which cannot be subsumed under a testing guideline, but which are never-
theless well documented and scientifically acceptable.
3 Not reliable
Studies or data [...] in which there were interferences between the measuring system and the test sub-
stance or in which organisms/test systems were used which are not relevant in relation to the exposure
(e.g. unphysiological pathways of application) or which were carried out or generated according to a
method which is not acceptable, the documentation of which is not sufficient for assessment and which
is not convincing for an expert judgment.
4 Not assignable
Studies or data [...] which do not give sufficient experimental details and which are only listed in short
abstracts or secondary literature (books, reviews, etc.).
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Table 2. Summary of the selected toxicity studies for DIPE risk assessment
Type of study Substance
tested
Species
number, duration
sex/group
Administration route
doses
NOEL Reference Klimisch
score
Subchronic and
developmental
toxicity
DIPE Rat
Subchronic:
14/sex/group
13 weeks (6 hr/day,
5 day/week)
Developmental:
22 female/group
6-15 gestation days
(6 hr/day)
Inhalation
Subchronic:
480; 3,300; 7,100 ppm
Developmental:
430; 3,095; 6,745 ppm
Subchronic: 480 ppm
based on an increase in
weight of liver and
kidney at 3,300 and
7,100 ppm
Developmental: 430
ppm based on an
increase in the
incidence of
rudimentary 14th ribs at
3,095 and 6,745 ppm
10 2
Subchronic
neurotoxicity 
DIPE Rat
10/sex/group
13 weeks
Inhalation
450; 3,250; 7,060 ppm
3,250 ppm based on a
slight decrease in motor
activity observed in
females exposed to
7,060 ppm
17 2
Genotoxicity
in vitro
DIPE S. typhimurium,
E. coli, S. cerevisiae,
Rat liver RL4 cell line
In vitro NA 19 2
Carcinogenicity DIPE Rat
100/sex/group
78 week (4 day/week)
Oral
250; 1,000 mg/kg
250 mg/kg based on an
increase in total
malignant tumors at
both doses
24 2
Subchronic
toxicity
G/DIPE Rat
10 or 20 sex/group
13 weeks + 4 weeks
recovery
Inhalation
2,000; 10,000;
20,000 mg/m3
10,000 mg/m
3
 based on
the reticulocyte count
6 1
Subchronic
neurotoxicity
G/DIPE Rat
5/sex/group
13 weeks
Inhalation
2,000; 10,000;
20,000 mg/m3
20,000 mg/m
3
 due to
the lack of effect on
investigated parameters
7 1
Developmental
toxicity
G/DIPE Rat
25 female/group
5-20 gestation days
Inhalation
2,000; 10,000;
20,000 mg/m3
Maternal: 2,000 mg/m3
based on a transient
reduction in weight gain
at 10,000 or 20,000
mg/m
3
Fetal: 10,000 mg/m3
based on decreased
foetal body weight
8 1
Reproductive
toxicity
G/DIPE Rat
26/sex/group
Female and male prior
to mating:
10 weeks and during
the 14-day mating
period.
Mated females:
- 0-19 gestation day
- 5-28 lactation day
Inhalation
2,000; 10,000;
20,000 mg/m
3
Parental: 2,000 mg/m3
based on increased liver
weights in the mid and
high dose groups
Offspring: 20,000
mg/m3 due to the lack
of effect on
reproductive parameters
9 1
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DIPE studies.
• Subchronic toxicity: Dalbey and Feuston (12) inves-
tigated the subchronic toxicity of DIPE (purity: 92%) in
Sprague-Dawley-derived rats [Tac:N(SD)fBR]. Three groups
of rats (14/sex) were exposed to DIPE at concentrations of
480, 3,300, or 7,100 ppm for 13 weeks in 1-m3 chambers.
Gas chromatography (GC) analysis of samples of air from
the chambers was routinely performed and showed that
DIPE represented 91~92% of the total vapours. The
remaining components were identified by GC/mass spec-
trometry. Airflow was controlled and provided at least 12
air changes/hr. The Authors used both an unexposed and a
sham-exposed control groups. During the course of exper-
iment, body weights were recorded weekly and clinical
signs daily. Blood samples were taken following the last
exposure for haematological and serum chemistry analy-
sis. All animals were necropsied. The following organs of
each animal were weighed: adrenals, kidney, spleen, brain,
liver, testes, epididymides, ovaries, thymus, heart, pros-
tate, and uterus. The following tissues were processed
from all sham-exposed and high-dose animals: adrenals,
ovaries, sternum, pancreas, brain (three sections), salivary
gland, eye, optic nerve, spleen, heart, stomach, colon, tes-
tes, duodenum, thymus, kidneys, thyroid, liver, lymph
nodes, lung (left lobe), nasal turbinates, thigh muscle, skin
(six sites), urinary bladder, sciatic nerve, seminal vesicles,
preputial glands, and any gross lesions. Histopathology
was carried out on liver and kidney of male rats exposed
to 3,300 ppm. The morphology and number of sperm were
evaluated in epididymes in both control groups and the high-
concentration group. The left testis was weighed and used
for determination of the number of testicular spermatids.
DIPE induced no change in clinical signs. DIPE did not
adversely affect haematology and serum chemistry end-
points with the exception of a 30% increase in cholesterol,
observed only in males exposed to the highest concentra-
tion (7,100 ppm). Exposure to DIPE 3,300 and 7,100 ppm
caused a dose-related increase in the liver weight, in both
sexes. At 7,100 ppm, hypertrophy of liver cells was
observed in males only. Kidney weight was increased in
males exposed to DIPE 3,300 and 7,100 ppm, and in
females exposed to 7,100 ppm. Microscopic examination
revealed an increase in hyaline droplets in the proximal
convoluted tubules only in males exposed to 7,100 ppm.
No other exposure-related changes were observed micro-
scopically. The numbers of sperm and spermatids were not
affected by exposure to DIPE. At 480 ppm, DIPE caused
no change in any of the parameters investigated.
The GLP status of the study is unknown. However, the
study is well documented and essentially complies with
the EPA Guideline on 90-Day Inhalation Toxicity (13)
with relatively minor deviations, which included a lower
number of animals per experimental group (14 instead of
recommended 20), not measuring the blood clotting
potential and lack of ophthalmological examination. We
assigned a Klimisch score 2 to this study.
• Developmental toxicity: Dalbey and Feuston (12)
also investigated the developmental toxicity of inhaled
DIPE. Sprague-Dawley rats (22 female/group) were exposed
on 6-15 gestation days (GD) to DIPE (purity: 92%) 430,
3,095, or 6,745 ppm and sacrificed on day 20. There were
also two control groups: untreated and sham-exposed. Body
weights and food consumption were recorded on days 0,
6, 13, 16, and 20. The same haematology and serum
chemistry parameters as in the subchronic study were
evaluated. All organs were examined grossly. The number
of corpora lutea per ovary and the gravid uterine weight
were recorded. Uterine contents were examined and the
Table 2. Continued
Type of study Substance
tested
Species
number, duration
sex/group
Administration route
doses
NOEL Reference Klimisch
score
Immunotoxicity G/DIPE Rat
5 female/group
4 weeks
Inhalation
2,000; 10,000;
20,000 mg/m3
10,000 mg/m
3
 based on
decrease in IgM
antibody forming cell
response to the T-
dependent antigen sheep
red blood cells at
20,000 mg/m
3
10 1
Genotoxicity
in vivo
G/DIPE Rat
5/sex/group
4 weeks
Inhalation
2,000; 10,000;
20,000 mg/m
3
20,000 mg/m
3
 due to
the lack of effect on
micronucleated
immature erythrocytes
and sister chromatid
exchange
11 1
DIPE: diisopropyl ether. G/DIPE: vapour mixture of Gasoline and diisopropyl ether. NOEL: no observed effect level. NA: not applicable.
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numbers of implantation sites, early and late resorptions,
and live and dead foetuses were also recorded. Fetuses
were weighed and grossly examined for external anoma-
lies, after which fetuses of each litter were equally distrib-
uted between two groups and examined for visceral
anomalies after fixing in Bouin’s solution and for skeletal
anomalies after fixing in 95% ethanol.
Dams exposed to the highest concentration of 6,745
ppm had a significant reduction in body weight gain and
decrease in food consumption. No treatment-related effects
were noted at the time of macroscopic examination. Expo-
sure to DIPE did not influence any parameter of reproduc-
tion and fetal development. A statistically significant
increase in the incidence of rudimentary 14th ribs was
observed at 3,095 and 6,745 ppm. All of the observed 14th
ribs were rudimentary except for two fetuses from each of
the mid- and high-dose groups that had either bilateral
short 14th ribs or bilateral short and rudimentary 14th ribs.
The biological significance of rudimentary ribs has long
been debated but the toxicological relevance of such find-
ings is still uncertain (14). The Authors of the study con-
cluded that this effect did not represent a conclusive
evidence of developmental toxicity. There was no appar-
ent toxicity, either maternal or fetal, at the lowest expo-
sure concentration, 430 ppm.
The study met the requirements of the OECD guideline
‘Prenatal Developmental Toxicity Study’ (15) and the EPA
guideline for prenatal developmental toxicity studies (16).
Its GLP status is unknown. We assigned a Klimisch score
2 to this study.
• Subchronic neurotoxicity: Rodriguez and Dalbey
(17) investigated neurotoxicity in rats using a functional
observational battery (FOB), automated motor activity,
and neuropathology assessment. Sprague-Dawley rats
were exposed for 13 weeks by inhalation to DIPE (purity
~92%) 0, 450, 3,250, or 7,060 ppm (10/sex/group). Expo-
sure methods and monitoring were the same as those for
the subchronic study (12). Sham-exposed and exposed rats
were housed continuously and individually in 1-m3 inhala-
tion chambers except during behavioural testing. The FOB
consisted of initially observing home-cage positioning,
posture, and reaction to removal from the cage. This was
followed by evaluation for exophthalmus/palpebral clo-
sure, lacrimation, salivation, pupillary response, palpebral
reflex, and pinna reflex (scored by the response of the ani-
mal as the hair on the inside of the pinna was touched).
The animals were then observed for open field behaviour.
Reactions to the approach of a pencil, finger snap, and tail
pinch were ranked and recorded. Finally, fore- and hind
limb grip strength was measured. The FOB was repeated
following 2, 4, 8, and 13 weeks of exposure, motor activ-
ity was determined following 4, 8, and 13 weeks of expo-
sure. Automated motor activity was assessed for 30 min in
figure-8 mazes after the completion of the FOB. Body
weights were recorded weekly and signs of toxicity daily,
prior to each exposure. Following the final determination
of motor activity, brain, spinal cord, gasserian and dorsal
root ganglia, and sciatic nerve of six animals/group/sex
exposed to 0 or 7,060 ppm DIPE were removed, processed
for embedding in paraffin or glycol methacrylate and sec-
tioned for microscopic pathologic evaluation. Few statisti-
cally significant changes in some FOB endpoints were
found at weeks 2 and 4 but with no dose-relationship. The
pinna reflex (scored by the response of the animal as the
hair on the inside of the pinna was touched) was reduced
compared to controls at week 2 only in the low dose
group. The unperturbed activity level was lower than in
controls in the low- and high-dose females at week 4. In
females, exposure to highest DIPE concentration was
related to a slight decrease (−15 to −20%) in motor activ-
ity in the figure-8 maze (statistically significant at week
4). In contrast, motor activity at week 8 was slightly
increased in females exposed to DIPE 450 ppm. Micro-
scopic examination revealed no apparent change of tis-
sues from the nervous system.
The study complied with the EPA Guideline for neuro-
toxicity screening (18). The GLP status is unknown but
the study is well documented. We therefore assigned a
Klimisch score 2 to the study.
• Genotoxicity in vitro: Genotoxicity of DIPE (purity
> 98.5%) was investigated in vitro by Brooks and co-
workers (19) performing bacterial mutation assays, a yeast
assay for mitotic gene conversion, and assays for chromo-
some damage in cultured mammalian cells. For bacterial
mutation assays, the following strains of S. typhimurium
(TA1535, TA1537, TA1538, TA98 and TA100) and E. coli
(WP2 and WP2 uvr A, WP2 uvrApKM 101) were used at
a maximum DIPE concentration of 8,000 µg/mL. These
strains are in agreement with the combination of strains
recommended by the OECD guideline for bacterial reverse
mutation test in order to detect most types of mutagens
(20). Methods were overall similar to those of the OECD
guideline. However, the paper does not report information
on cytotoxicity or the presence of precipitate in the cul-
tures. The yeast assay for mitotic gene conversion used S.
cerevisiae JD1, heteroallelic at the histidine-4 and trypto-
phan-5 loci, which is one of the strains listed in the rele-
vant OECD guideline 481 (21). The number of replicates
and exposure concentrations (maximum DIPE concentra-
tion 5 mg/mL), the use of positive controls, and the perfor-
mance of the test were in agreement with the OECD 481
guideline. The Authors state that the final experimental
conditions were based on the results of a first experiment,
taking into account the effect of the test material on cell
viability. The assays for chromosome damage in cultured
mammalian cells used rat liver RL4 cell line (this epithe-
lial-type cell line was derived in the same laboratory in
which the genotoxicity study was performed). In this assay,
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metabolic activation by S9 was not used because the RL4
cells are metabolically competent. The conditions of the
test, including the selection of the exposure concentra-
tions (based on growth inhibition results, maximum DIPE
concentration 1,200 µg/mL), the use of positive controls
and the performance of the test were in agreement with the
OECD 473 guideline (22).
DIPE did not induce reverse gene mutation in bacteria,
mitotic gene conversion in yeast or chromosome damage
in mammalian cells, thus DIPE has no potential to cause
point mutations neither to be clastogen/aneugenic.
Recommendations on genotoxicity testing and data inter-
pretation for pharmaceuticals intended for human use are
laid down in the ICH S2(R1) guideline (23). For the bacte-
rial mutation assay, the ICH S2(R1) protocol recommen-
dations are the same as those of the OECD guideline (21).
The other two cytogenetic assays used with DIPE are cur-
rently not included in the core in vitro test battery reported
in ICH S2(R1) guideline. In particular, the mitotic gene
conversion in yeast has been now superseded by in vitro
mammalian cell systems including metaphase chromo-
some aberration/micronucleus/mouse lymphoma L5178Y
cell thymidine kinase gene mutation assays. In addition, in
vitro metaphase chromosome analysis is now preferably
detected in peripheral blood. However, the rat liver cell
line used for DIPE screening can be considered adequate
for detection of structural and numerical chromosome
aberrations also considering the inherent presence of met-
abolic activation systems in the cell line selected. No
explicit information on cytotoxicity was reported in the
study, on which basis the maximum concentration to be
tested should be selected, but it can be reasonably assumed
that no toxic concentration levels have been assayed in the
wide range tested and that the negative result is suffi-
ciently reliable. Although GLP status of genotoxicity stud-
ies is unknown, overall, the genotoxicity study report of
Brooks and co-workers was considered reliable with
restrictions (Klimisch score 2).
• Carcinogenicity: The research group of the Ramazz-
ini Foundation investigated DIPE carcinogenicity in Sprague-
Dawley rats (24). DIPE (purity > 98%) was administered
by gavage in 1 mL olive oil solution at concentrations of
0, 250 or 1,000 mg/kg body weight to groups of 100/sex
rats. DIPE was administered daily, 4 days weekly, for 78
weeks. The animals were then maintained under control
conditions until spontaneous death. The study ended after
163 weeks of treatment with the death of the last animal at
171 weeks of age. Body weights, water and food con-
sumption, status and behaviour of animals were examined
daily, clinical examination for gross changes every 2
weeks. Blood or urine were not analysed during the study.
Histopathology was performed on most of the organs rec-
ommended by the OECD guideline 451 for carcinogenicity
studies (25) and on any other organ or tissue with patho-
logic lesions. No significant differences were observed in
food consumption, body weight, behaviour, or non-onco-
logical pathological changes between DIPE-treated and
control animals. A decrease in survival was observed in
DIPE-treated males versus controls in the period between
the 56th and 88th week of age.
In DIPE-treated rats, an increase in total malignant tumors
was observed in both males and females at both doses but
with no clear dose-response relationship. In particular, DIPE
treatment was linked to an increase in the incidence of carci-
nomas of the ear duct, an increase in the incidence of glial
malignant tumors of the brain, an increase of hemolymphore-
ticular neoplasias, a slight increase in malignant sarcomas
of the uterus and vagina. The onset of some interstitial cell
adenomas of the testis was also noted in the treated group.
The validity of the findings of some carcinogenicity
studies conducted by the research group of the Ramazzini
Foundation has been questioned (26-28). Criticisms focused
on the general study protocol, which differs from those of
international risk assessment guidelines. Particular causes
of concern have been the retention of test animals until
death and the use of non pathogen-free conditions, the
high background incidence of chronic inflammatory changes
in vital organs and tissues, and the uncertainty about the
correctness of the diagnoses of some tumour types. In the
DIPE study (as in other cancer studies performed by the
Ramazzini Foundation), rats were observed at necroscopy
after natural death occurring at approx. 3 years of age
(DIPE treatment covered half of this period) while cancer
bioassays are usually terminated at 2 years. Termination at
2 years allows maximizing the number of control and
treated animals available at the same age for comparisons.
In addition, it minimizes late-developing background tumors
that may limit the ability to detect chemical-induced effects.
On the other hand, the longer duration of the Ramazzini
Foundation studies may allow detecting late-stage or late-
developing cancers. As noted by Gift and co-workers (29),
the longer duration of the Ramazzini Foundation studies
has been important for the detection of later-occurring
tumors for a number of chemicals. Recently, the U.S.
National Toxicology Program (NTP) and EPA sponsored a
comprehensive review of the Ramazzini Foundation stud-
ies by an expert team (29). The study group reviewed the
procedures and tumor diagnoses of the Ramazzini Foun-
dation, and examined evidence for a number of issues
raised regarding the studies performed by the Foundation.
The conclusion was that Ramazzini Foundation results are
generally consistent with those of the NTP and other labo-
ratories and that these studies may be informative for
health risk assessment when reviewed on a case-by-case
basis. There are doubts with regard to lymphoma/leuke-
mia diagnoses, because the types of lymphomas reported
in exposed groups have also been observed in older
untreated Sprague-Dawley rats in the Ramazzini Founda-
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tion colony, and the fraction of Ramazzini Foundation
control groups with a lymphoma/leukemia rate > 10% has
increased with time (29). In addition, according to the NTP
review of the Ramazzini Foundation studies, for lympho-
mas and leukemias pathological determinations via light
microscopy evaluations are problematic, especially when
confounded by infiltrates from an infectious disease (30).
On the other hand, an increase in lymphomas/leukemias-
was only found in a minority of the Ramazzini Founda-
tion studies (~5%) (29). Moreover, results of the Ramazzini
Foundation studies were consistent with other studies for
some chemicals (especially those metabolized to formal-
dehyde). Therefore, available data do not support a gener-
alized incorrect attribution of lymphomas/leukemias to
test substances in the Ramazzini Foundation studies. Con-
cerning GLP, the Ramazzini Foundation Authors claimed
that experiment was GLP compliant. Concordantly, Gift
and co-workers (29) noted that independent reviews and
available Ramazzini Foundation documentation suggested
that quality control procedures associated with GLP were
in place at the Ramazzini Foundation. In particular, in the
cited NTP review of the Ramazzini Foundation studies
(30), the Authors reported “very organized, clean facilities”
and that “standard operating procedures, GLP documents,
and necropsy records were within GLP expectations” after a
tour of the Ramazzini Foundation laboratory and archives.
Deficiencies of the DIPE study were the following: a)
only 2 doses were investigated instead of the 3 dose lev-
els recommended by the OECD 451 guideline (25) and
other international guidelines; b) survival-adjusted analy-
ses (tumor rates and trend analyses) were not performed
even though data suggested that survival may differ between
treated and control groups; c) a complete analysis and sta-
bility data of the test substance or formulation were not
provided. Overall considered, we concluded that these
methodological deficiencies are not sufficient to invali-
date the study findings and evaluated the Ramazzini Foun-
dation study as reliable with restrictions (Klimisch score 2).
Studies with gasoline/DIPE mixtures. The Research
Group of the American Petroleum Institute performed a
series of studies investigating the toxicity of gasoline con-
taining fuel oxygenate additives, including DIPE. The
studies included evaluation of subchronic toxicity, neuro-
toxicity, genotoxicity, immunotoxicity, reproductive and
developmental toxicity in rats. In all studies, the animals
were exposed to 0 (control), 2,000, 10,000 or 20,000 mg/
m3 of gasoline alone or gasoline/DIPE (G/DIPE) vapour
(generation and composition is described in a separate paper
[31]). DIPE represented 17.8% of the G/DIPE vapour (31).
The Authors affirm that these studies were conducted in
accordance with EPA GLP (32).
• Subchronic toxicity: CD (Crl: CD@ IGS BR) albino
rats (10 or 20 sex/group) were exposed to gasoline or G/
DIPE vapour for 13 weeks (6). During each exposure,
measurements of airborne concentrations were performed
in the animals’ breathing zone at least 4 times. In addi-
tion, samples were collected weekly and analysed by GC
to characterize at least 18 major components. At the end
of the exposure period, recovery (4 weeks) was studied in
control and high dose rats. During the exposure period,
rats were observed for mortality and signs of severe toxic
or pharmacologic effects, body weight and food consump-
tion were monitored. All animals received ophthalmoscopic
examinations pre-test and at study termination. Haemato-
logical and clinical chemistry analyses were performed on
blood samples collected after 4 and 13 weeks of expo-
sure. Necropsies were conducted on 10/sex/group, and on
all of the recovery group animals. Organs were trimmed
and weighed, tissues were excised and preserved for histo-
pathology in agreement with the recommendations of the
OECD guideline for subchronic inhalation toxicity (33).
The results showed that G/DIPE caused no significant
change in the examined endpoints with the exception of
mild haematological changes. In males, there was a decrease
(21~23% in the high dose group) in reticulocyte counts,
which was dose-related. The decrease was reversible in
the low- and mid- but not in the high-concentration exposed
group. In females, there were a decrease (−35%) in mono-
cytes but only in the high concentration group. Increased
kidney weight and light hydrocarbon nephropathy were
observed in treated male rats exposed to gasoline alone, G/
DIPE or gasoline mixed with other oxygenate additives.
These changes were reversible or nearly reversible after 4
weeks recovery. The microscopic lesions observed were
consistent with changes associated with accumulation of
alpha-2 microglobulin within epithelial phagolysosomes.
It is widely recognized that hyaline droplet nephropathy
following exposure to chemicals inducing excessive accu-
mulation of alpha 2u-globulin is unique to male rats and is
considered not to be relevant to humans (34) as also
acknowledged by the EPA (35). Based on these results, the
Authors considered the G/DIPE 10,000 mg/m3 exposure
level as the NOEL. This conclusion can be shared taking
into account that the decrease in reticulocyte counts in
males exposed to G/DIPE 2000 and 10,000 mg/m3 was
very mild and transient.
The study protocol, conduct and report were compliant
with the OECD guideline 413 (33). The study was judged
to be reliable without restrictions (Klimisch score 1).
• Neurotoxicity: O’Callaghan et al. (7) investigated
neurotoxicity of G/DIPE. Sprague-Dawley rats (5/sex/
group) were exposed to DIPE or G/DIPE following the
same protocol as in the subchronic toxicity study. FOB
and motor activity were conducted once before initiation
of exposures and again during the 4th, 8th and 13th week
of exposures. Evaluations were conducted on non-expo-
sure days at least 16 hr post-exposure. Neuropathology
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was examined in 10 rats (5 males and 5 females) exposed
to the highest concentration. After perfusion and fixation,
the brain, eye with optic nerve, spinal cord, trigeminal
ganglia, dorsal root ganglia, dorsal and ventral root fibers,
lungs and trachea were processed by standard techniques,
embedded in paraffin and sectioned at approximately 6
microns. Peripheral nerves were post-fixed in 1% osmium
tetroxide, processed and embedded in epoxy resin, sec-
tioned at approximately two microns and stained with
toluidine blue. Changes in glial fibrillary acidic protein
(GFAP) levels in areas of the brain were examined by
immunoassay. GFAP is a biomarker of neurotoxicity and
the assay may reveal effects at doses below those causing
light microscopic evidence of cell loss or damage (36).
The results showed some statistically significant changes
in the motor activity. However, these changes were incon-
sistent and not dose-related. G/DIPE did not induce statis-
tically significant changes in any of the FOB measures, in
brain measurements or weights, GFAP levels. No micro-
scopic changes attributable to test substance effect were
observed in brain, spinal cord, eyes, peripheral nerves, or
ganglia among the high dose exposed animals. These
results show that exposure to G/DIPE cause no significant
neurotoxicity.
The study complied with the EPA guideline for neuro-
toxicity screening (18). The study also met the require-
ments of the OECD guideline on neurotoxicity studies in
rodents (37). The study was therefore judged to be reli-
able without restrictions (Klimisch score 1).
• Developmental toxicity: Roberts et al. (8) investi-
gated the developmental toxicity of G/DIPE. Sprague-
Dawley female rats (25/group) were exposed on GDs 5-
20. Dams were sacrificed by CO2 asphyxiation on GD 21.
Clinical signs, body weights and food consumption were
monitored throughout the study. A gross necropsy was
performed on all confirmed-mated females. Uterine weights
with ovaries attached were recorded at the time of nec-
ropsy, uterine contents were examined, corpora lutea and
the numbers and locations of implantation sites, early and
late resorptions, and live and dead (alive or dead in utero)
fetuses were counted. Fetuses were weighed and exam-
ined externally for gross malformations and variations.
The viscera of approximately one-half of the fetuses of
each litter were examined by fresh dissection. Sections of
the Bouin’s-fixed fetal heads were examined for the pres-
ence of abnormalities. The remaining live fetuses (alive in
utero) were examined for the presence of bone and carti-
lage malformations and ossification variations. Evalua-
tions of dams and foetuses were blinded.
All rats survived to study termination. No significant
clinical signs were observed during the study. The num-
ber of pregnant animals was similar to controls. Exposure
to G/DIPE 10,000 or 20,000 mg/m3 caused a transient
reduction in maternal weight gain during the early days of
the exposure period and was partially resolved by GD 21.
Exposure to G/DIPE 10,000 or 20,000 mg/m3 also caused
a decrease in food consumption that did not exceed 10%.
These maternal effects were not observed in the groups
exposed to gasoline alone. Implantation sites, resorptions,
mean litter size, corpora lutea, fetal number of viable fetuses
and fetuses per litter were comparable to controls. Fetal
body weight in the G/DIPE 20,000 mg/m3 group litters
was statistically significantly lower for females (5%) and
combined sexes (3.3%) compared to controls. Fetal body
weight was also lower in the groups exposed to gasoline
alone but the Authors of the study considered this as a
spurious finding because fetal weights in all gasoline expo-
sure groups were within the range of the laboratory con-
trol groups and no dose-response occurred. It should be
also taken into account that a decreased body weight was
observed in the rats exposed to G/DIPE or G/TAME but
not to other gasoline/oxygenate additive mixtures. We
therefore concluded that the decrease in fetal body weight
observed with G/DIPE should be attributed to DIPE.
Exposure to G/DIPE did not induce significant increases
in fetal external variations, visceral variations or malfor-
mations or skeletal malformations. Based on these results,
the Authors established a maternal NOEL value of 2,000
mg/m3. Developmental NOEL was established at 10,000
mg/m3 due to the decreased fetal body weight found in the
20,000 mg/m3 exposure group.
The study met the requirements of the relevant OECD
(15) and EPA (16) guidelines and was judged to be reli-
able without restrictions (Klimisch score 1).
• Reproductive toxicity: Reproductive toxicity was
assessed in a one-generation study in rats (9). Sprague
Dawley rats (26/sex/group) were exposed 7 days/week for
one generation. Parental males and females received 70
consecutive days (10 weeks) of exposure prior to mating
and continued to be exposed during the 14-day mating
period. Mated females were exposed daily from gestation
day (GD) 0 through GD 19, not exposed after GD 19
through lactation day (LD) 4, and again exposed from LD
5 until weaning on LD 28. Pups were observed for sex,
number of live and dead pups and pup abnormalities. Pups
dead at delivery were identified as stillborn or live-born
found dead based on the evaluation of lung floatation.
Thereafter litters were observed twice daily and litter size
was recorded daily. Pups were examined and weighed up
to LD 28, when they were terminated. Macroscopic exam-
inations were performed on up to three randomly selected
pups/sex/litter on LD 28 including identification of any
structural abnormalities or pathological changes. All remain-
ing pups were examined for external abnormalities and
sacrificed. Brain, spleen and thymus gland were weighed
from one randomly selected pup/sex/litter. All parental
male animals were sacrificed during the lactation period
for a total of 16~20 weeks of exposure and all parental
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females were sacrificed on their LD 28. Selected organs
were weighed and organ/body weight and organ/brain
weight ratios calculated. Macroscopic examinations were
performed on all parental rats and histological evaluations
of the tissue samples from the organs of rats in the control
and 20,000 mg/m3 groups were performed. Reproductive
organs from all male and bred female rats in control and
high dose groups were evaluated. Examination of all paren-
tal females included a vaginal smear at time of necropsy to
determine stage of estrus and a count of uterine implanta-
tion scars if present. Ovary histopathology included evalu-
ation of the primordial follicle population, number of
growing follicles and corpora lutea. Right testes and right
epididymis from each animal were removed intact, weighed
and fixed. Sperm evaluations included motility, testicular
homogenization-resistant sperm and cauda epididymal sperm
count and sperm morphology.
In parental males, G/DIPE 10,000 and 20,000 mg/m3
caused an increase in the weight of liver, epididymides,
and seminal vesicles/coagulating gland. The changes in
male organ weights were considered as minor by the Authors
and did not occur in a dose-responsive manner. The Authors
concluded that these effects were unlikely to be due to
exposure or of toxicological relevance. No remarkable his-
topathological change was found. G/DIPE had no effect
on litter size (pups/litter, pups born dead/litter), number of
implantation sites/litter, pup birth weight, offspring sur-
vival, or sex ratio. Male and female fertility or reproduc-
tive performance, oestrus cyclicity and semen parameters
were comparable between exposed and control groups. As
found also in the subchronic toxicity study with G/DIPE (6),
exposure to gasoline alone or mixed with DIPE caused
increases in male kidney weights and microscopic evidence
of light hydrocarbon nephropathy. The parental NOEL
was 2,000 mg/m3 based on increased liver weights in the
mid and high dose groups. Reproductive NOEL was 20,000
mg/m3 due to the lack of effect on reproductive parameters.
The study protocol and conduct complied with the OECD
on one-generation reproduction toxicity study (38). The
Authors claimed that their study met the requirements of
the relevant EPA guideline (39), which may be correct but
with the limitation that this was a one-generation study
whereas the guideline concerns two-generation studies.
We assigned a Klimisch score 1 to the study.
• Immunotoxicity: White and co-workers (10) inves-
tigated immunotoxicityin female Sprague Dawley rats (5/
group). They used the IgM antibody-forming cell (AFC)
response to the T-dependent antigen sheep red blood cells
(sRBC), also known as the plaque assay. Animals were
exposed for 4 weeks and immunized by intravenous injec-
tion of sRBC, four days prior to sacrifice. After sacrifice,
spleens were removed, weighed and processed for deter-
mination of IgM antibody response using a modified hae-
molytic plaque assay of Jerne. Cells/spleen, AFCs/106
spleen cells, and AFC/spleen were determined.
In rats exposed to the lowest G/DIPE level of 2,000 mg/
m3 there was a statistically significant increase in the
spleen relative weight of 21%. However, this effect was
not dose dependent and was not considered by the Authors
to be biologically significant. There was no effect on the
relative weight of the thymus. G/DIPE had no effect on
spleen cell numbers but induced a decrease in IgM anti-
body forming cell response to the T-dependent antigen
sRBC which was statistically significant with the highest
exposure level of 20,000 mg/m3 (−63% as compared to the
control group). The NOEL was therefore 10,000 mg/m3.
In the same study, a similar effect of depression of the
humoral immune response was also observed following
exposure to gasoline/ethanol and gasoline/ETBE, but not
following exposure to gasoline alone, gasoline/MTBE, gas-
oline/TAME or gasoline/t-butyl alcohol.
The study was performed in agreement with the recom-
mendations of the EPA guideline on Immunotoxicity (40)
and was considered reliable without restrictions (Klimisch
score 1). 
• Genotoxicity in vivo: Genotoxicity was investigated
in Sprague Dawley rats (5/sex/group) exposed for 4 weeks
(6 hr/day, 5 days/week) using the bone marrow micronu-
cleus and the sister chromatid exchange (SCE) tests (11).
Rats dosed with cyclophosphamide were used as positive
control.
G/DIPE caused no significant increases in of micronu-
cleated immature erythrocytes nor in SCE.
Test procedures were in accordance with the relevant
EPA guidelines (41,42). The study was considered to be
reliable without restrictions (Klimisch score 1).
Metabolism. We found no study investigating the
metabolism of DIPE but retrieved several studies investi-
gating the metabolism of structurally related compounds,
namely aliphatic ethers with low molecular weight. Ber-
nauer and co-workers (43) investigated the metabolic
pathways of MTBE and ETBE in rats following exposure
to the 12C- and 13C-labeled ethers. The product of O-deal-
kylation of both ethers, tert-butyl alcohol (tert-butanol)
was found in the urine as a minor metabolite. Compounds
deriving from further oxidation of tert-butanol, 2-methyl-
1,2-propanediol and 2-hydroxyisobutyrate, were major
metabolites found in the urine along with small amounts
of 13C. The Authors also investigated the biotransforma-
tion of the initial metabolite of the ethers, tert-butanol.
They found that 2-methyl-1,2-propanediol, 2-hydroxy-
isobutyrate and tert-butanol sulphate were the major uri-
nary metabolites, while minor metabolites were [13C]-
acetone, tert-butanol, and tert-butanol glucuronide. Based
on these findings the following metabolic pathway was
proposed. The ethers undergo oxidative dealkylation to
form tert-butanol; tert-butanol can undergo conjugations
Permitted Daily Exposure for DIPE 121
plSSN: 1976-8257 eISSN: 2234-2753
reactions or be oxidized to 2-methyl-1,2-propanediol; the
latter can be further oxidized to 2-hydroxyisobutyrate.
Amberg and co-workers subsequently found that follow-
ing exposure to MTBE or ETBE, 2-hydroxyisobutyrate
was the major, and tert-butanol and 2-methyl-1,2-propane
diol the minor urinary metabolites, both in rats and humans
(44). These findings are consistent with those of Bernauer
and co-workers (43) and indicate that the metabolic path-
way in humans is the same as in rats. Shamsipur and co-
workers (45) characterized the metabolic biotransforma-
tion of MTBE by human CYP2A6. Their results indicated
that the first measurable metabolite was tert-butanol.
Other identified metabolites were tert-butoxy methanol, 2-
methyl-1,2-propanediol and 2-hydroxyisobutyrate. Analy-
sis of the culture media also revealed the presence of
formaldehyde, acetone and acetaldehyde (which accord-
ing to the Authors may also be an artefact). The proposed
metabolic pathway in presence of CYP2A6 is therefore
the following: MTBE first undergoes oxidative dealkyla-
tion to form tert-butoxy methanol, which spontaneously
dismutates to tert-butanol and formaldehyde; tert-butanol
is oxidized to 2-methyl-1,2-propanediol, which is further
oxidized to 2-hydroxyisobutyrate. To explain the presence
of acetone, the Authors hypothesize that 2-hydroxyisobu-
tyrate degrades to 2-propanol, which is then oxidized to
acetone. Therefore, the oxidizing metabolic pathway pre-
viously proposed by Bernauer and co-workers (43) was
essentially confirmed even though with additional steps.
Overall, all available studies indicate that oxidative O-
dealkylation is the first metabolic step shared by alkyl
ethers, resulting in the formation of an alcohol and a car-
bonyl compound, which can be further oxidized. In the
case of DIPE, the first metabolites formed from oxidative
O-dealkylation should be isopropanol and acetone. The
major metabolic pathway of isopropanol is oxidation to
acetone, catalysed mainly by alcohol dehydrogenase. Ace-
tone can be further oxidized to acetol (hydroxyacetone)
and methylglyoxal and subsequent conversion to glucose
(46), a process that also occurs in man. An alternative
pathway may occur which involves the conversion of ace-
tol to L-1,2-propanediol and subsequent conversion of L-
1,2-Propanediol to L-lactaldehyde, and of L-lactaldehyde
to L-lactic acid (46). Other metabolites may also be
formed, which are converted to glucose and other prod-
ucts of intermediary metabolism.
In conclusion, available rat and human data suggest that
biotransformation of DIPE should not lead to reactive
toxic metabolites.
Other data.
• Human data: The DIPE full record in the Hazard-
ous Substances Data Bank (HSDB) reports the results of
short-term human exposure to DIPE under controlled con-
ditions. Exposure to 500 ppm over a 15 min period caused
no irritation, but irritation of the eyes and nose was noted
at 800 ppm for 5 min with some respiratory discomfort
(47).
• Occupational exposure limits: For the National
Institute for Occupational Safety and Health (NIOSH), the
10 hr time-weighted average is 500 ppm. 
NOELs.
• Subchronic toxicity: DIPE caused no change in any
of the parameters investigated at a concentration of 480
ppm (12), corresponding to 2,006 mg/m3. For G/DIPE the
NOEL was 10,000 mg/m3 in the main subchronic study (6)
based on the reticulocyte count data. Because DIPE was
17.8% of the generated vapour, this value corresponds to
DIPE 1,780 mg/m3. An increase in liver weights was found
in reproductive toxicity study in mid and high dose G/
DIPE groups (with a NOEL of 2,000 mg/m3, correspond-
ing to DIPE 356 mg/m3) (9) but not in the main sub-
chronic toxicity study. Exposure to DIPE alone caused an
increase in liver weight but only at 13,794 and 29,678 mg/
m3 (3,300 and 7,100 ppm). The reliability of the NOEL
value found in the reproductive toxicity study is therefore
uncertain.
• Developmental toxicity: Exposure to DIPE did not
influence any parameter of reproduction and foetal devel-
opment (12). A statistically significant increase in the inci-
dence of rudimentary 14th ribs was observed at 3,095 and
6,745 ppm but the biological significance and toxicologi-
cal relevance of such findings is still uncertain. Maternal
toxicity was found at 6,745 ppm because dams exposed to
this concentration had a significant reduction in body
weight gain and a decrease in food consumption. There
was no apparent toxicity, either maternal or foetal, at the
lowest exposure concentration, 430 ppm (1,797 mg/m3),
which is therefore the developmental NOEL. The results
of the G/DIPE developmental toxicity study (8) support
these findings because exposure to G/DIPE 10,000 or
20,000 mg/m3 (but not to gasoline alone) caused a tran-
sient reduction in maternal weight gain and slightly decreased
food consumption. G/DIPE 20,000 mg/m3, but not the
lower concentrations, also decreased the foetal body
weight. Maternal and developmental NOEL for G/DIPE
were therefore established at 2,000 and 10,000 mg/m3,
respectively, corresponding to a DIPE concentration of
356 and 1,780 mg/m3.
• Reproductive toxicity: Only data obtained with G/
DIPE area available (9). They indicate that reproductive
NOEL is 20,000 mg/m3 (3,560 mg/m3 of DIPE) due to the
lack of effect on reproductive parameters.
• Neurotoxicity: Exposure to DIPE (17) or G/DIPE
(7) did not induce any observable change of tissues from
the nervous system. There was no clear evidence of neuro-
behavioral changes induced by DIPE, with the possible
exception of a slight decrease in motor activity observed
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in females exposed to the highest DIPE concentration
(7,060 ppm). We therefore established the mid exposure
value of 3,250 ppm as the NOEL value for neurotoxicity.
Exposure to G/DIPE caused no change in any of parame-
ters investigated, taking into account that the transient
changes observed in the motor activity were inconsistent.
Therefore, the NOEL was established at 20,000 mg/m3.
• Immunotoxicity: There are no data for DIPE alone.
G/DIPE had no effect on the spleen cell numbers but
induced a decrease in IgM antibody forming cell response
to the T-dependent antigen sRBC which was statistically
significant with the highest exposure level of 20,000 mg/
m3 (−63% as compared to the control group). A similar
effect of depression of the humoral immune response was
not observed with gasoline alone and can therefore
attributed to DIPE. The NOEL was 10,000 mg/m3 (DIPE
concentration 1,780 mg/m3) (10).
PDE and acceptable limits. Both in vitro and in vivo
genotoxicity studies convincingly showed that DIPE is not
genotoxic. The lack of a genotoxic effect is also corrobo-
rated be the metabolism data of structurally related ethers,
which indicated that the metabolic pathway of such com-
pounds do not lead to the formation of reactive metabo-
lites. In light of its carcinogenic potential, DIPE can be
considered as a non-genotoxic carcinogen, and a PDE can
therefore be calculated according to the ICH Q3C guide-
line (Appendix 3), using the following formula:
PDE (mg/day) = NOEL (mg/kg/day)
× weight adjustment ÷ (F1 × F2 × F3 × F4 × F5)
(modifying factors)
The lowest among all NOEL values was 356 mg/m3, i.e.,
the maternal NOEL in the developmental toxicity study
with G/DIPE (8). The calculated absorbed dose was divided
by the maternal rat weight (0.374 kg) reported in the study
(8) and converted from discontinuous to a continuous
exposure. The resulting NOEL was 49 mg/kg/day, which
was then multiplied for the weight adjustment factor (50
kg) and divided by the following modifying factors: F1 =
5 (for extrapolation from rats to humans); F2 = 10 (for
inter-individual variability); F3 = 5 (for a 3-month study in
rodents); F4 = 10 (for carcinogenic activity). Since the no
effect level was established, no F5 was considered. Thus,
we derived a PDE value for DIPE of 0.98 mg/day, which
is in the range of the PDE values for ICH Q3C guideline
class 2 solvents.
Acceptable limits in a substance for pharmaceutical use
can be calculated according to the option 1 for class 2 sol-
vents of the ICH Q3C guideline:
Concentration (ppm) = 1,000 × PDE ÷ dose (g/day) 
In a worst-case scenario, using an exceedingly high
daily dose of 10 g/day, the allowed DIPE concentration in
the drug substance would be 98 ppm, which is in the range
of the concentration limits for ICH Q3C guideline class 2
solvents.
DISCUSSION
Literature search retrieved several toxicological in vivo
and in vitro studies carried out using either DIPE alone or
G/DIPE. Combined, these data allowed a comprehensive
toxicological evaluation of DIPE.
All studies but the carcinogenicity one used inhalation
exposure. Although we found no information on the inhaled
bioavailability of DIPE, organic solvents have high inhala-
tion bioavailability values (48) and inhalation route in rat
showed to be an appropriate method to assess the occupa-
tional hazards related to volatile solvents (49). Therefore,
it can be reasonably assumed that the inhaled bioavailability
is similar to that after oral intake. Concordantly, Amberg
and co-workers (50) estimated that the absorbed dose of a
compound structurally similar to DIPE, MTBE, was > 80%
and similar after both oral and inhalation exposure in man.
Therefore, we think that inhalation study data can be used
for risk assessment of residual solvents in pharmaceuti-
cals. Accordingly, the ICH Expert Working Group (ICH
EWG) used studies in which tetrahydrofuran and N-meth-
ylpyrrolidone were administered by inhalation for calcu-
lating the PDE values for these solvents (4, Appendix 3
part II and part III). The array of toxicological studies used
by ICH EWG in the re-evaluation of the PDEs for tetrahy-
drofuran and N-methylpyrrolidone was similar to that
used for DIPE. We therefore think that the available data
are adequate for a risk assessment of DIPE according to
the principles of the ICH Q3C guideline. In addition, the
Research Group organized by the American Petroleum
Institute performed a series of highly reliable (Klimisch
score 1) studies investigating the toxicity of G/DIPE mix-
tures. Because in each of these mixture studies the effect
of gasoline alone was also evaluated, it was possible to
extrapolate the toxic effects due to DIPE itself.
The main target organs of DIPE toxicity are the liver
and the kidney. In the liver, DIPE caused a dose-related
increase in weight (in both sexes) and hypertrophy of liver
cells (in males only). Kidney weight also tended to increase
mildly (+7 to +13%) in both sexes. Droplet nephropathy
was found in males only and the lesions observed were
consistent with changes associated with accumulation of
alpha-2 microglobulin within epithelial phagolysosomes.
It is known that these findings are not relevant to humans
because hyaline droplet nephropathy linked to accumula-
tion of alpha 2u-globulin is unique to male rats (34).
Exposure to G/DIPE but not to gasoline alone caused a
mild decrease (−22%) in reticulocyte count in males exposed
to the highest concentration. This effect might indicate
that bone marrow is also a target tissue. G/DIPE at the
Permitted Daily Exposure for DIPE 123
plSSN: 1976-8257 eISSN: 2234-2753
highest concentration also decreased the IgM antibody
forming cell response to the T-dependent antigen sRBC
(−63% in the group exposed to the highest G/DIPE con-
centration, no effect in the lower concentration groups) but
did not decrease the spleen cell number. This immunotoxic
effect was also observed with G/ethanol and G/ETBE.
DIPE was essentially devoid of any neurotoxicity because
exposure to DIPE alone or G/DIPE did not induce any
observable change of tissues from the nervous system.
Slight changes in neurobehavioral endpoints appeared to
be not related to exposure and inconsistent. Furthermore,
the biological significance of these subtle, reversible changes
is uncertain.
In pregnant rats, DIPE (both alone and as G/DIPE mix-
ture) caused a dose-dependent decrease in weight gain and
food consumption. Whether or not these maternal effects
are related to a decrease in the body weight of foetuses is
uncertain because a decrease in foetal weight (−3%) was
apparently found with G/DIPE but not with DIPE alone.
The available data allow defining a DIPE concentration
devoid of any teratogen effect. Following exposure to DIPE
alone, a statistically significant increase in the incidence of
rudimentary 14th ribs was observed at 3,095 (12,937 mg/
m3) and 6,745 ppm (28,194 mg/m3). The toxicological rel-
evance of such findings is uncertain (14). However, no
increase was found at 430 ppm (1,797 mg/m3). Concor-
dantly, exposure to G/DIPE 20,000 mg/m3 (corresponding
to DIPE 3,560 mg/m3) caused no increase in variations or
malformations. Data obtained with G/DIPE indicate that a
lack of effect on reproductive parameters at the highest tested
concentration (corresponding to DIPE 3,560 mg/m3).
With regard to the carcinogenic potential, available data
allow to exclude that DIPE is genotoxic, as shown in vitro
with DIPE alone (19) and in vivo with G/DIPE (11). Bel-
poggi and co-workers (24) found that exposure to DIPE
was associated to an increase in total malignant tumors.
We discussed above the issues concerning the reliability of
this study. We finally decided to consider the study reli-
able with restrictions (and therefore introduced a F4 fac-
tor in the calculation of PDE, as recommended by the ICH
Q3C guideline in case of non-genotoxic carcinogens) but
doubts on the reliability may persist. The main concern
refers to the diagnosis of lymphoma/leukemia, which led
the EPA to the decision of not relying on data from the
Ramazzini Foundation on lymphomas and leukaemias in
Integrated Risk Information System assessments. In the
DIPE study, the most frequent and most increased in treated
groups cancer endpoints were actually lymphoma and leu-
kaemia, and it is possible that exclusion of these endpoints
from the total would lead to different results for total
malignant tumors. If the results indicating that DIPE has a
carcinogenic effect are considered unreliable, the PDE
would increase to 9.8 mg/day.
We could not find any study investigating the metabo-
lism of DIPE. However, based on available data on the
metabolism in rat and human of structurally related ethers
we propose a metabolic pathway for DIPE leading to for-
mation of isopropyl alcohol (isopropanol) and acetone.
These two compounds can be further metabolized but this
should not lead to reactive toxic metabolites.
In conclusion, we calculated a PDE of 0.98 mg/day for
DIPE based on sufficiently reliable toxicity data. This
PDE value is in the range of those of ICH Q3C class 2 sol-
vents. This result might be considered for future regula-
tory decisions.
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